C57BL/6NCya-Angptl3em1/Cya
Common Name
Angptl3-KO
Product ID
S-KO-09081
Backgroud
C57BL/6NCya
Strain ID
KOCMP-30924-Angptl3-B6N-VA
Status
When using this mouse strain in a publication, please cite “Angptl3-KO Mouse (Catalog S-KO-09081) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Angptl3-KO
Strain ID
KOCMP-30924-Angptl3-B6N-VA
Gene Name
Product ID
S-KO-09081
Gene Alias
hypl
Background
C57BL/6NCya
Gene Full Name
angiopoietin-like 3
Modification
Conventional knockout
NCBI ID
Phenotype
Chromosome
Chr 4 (Mouse)
Application
--
Datasheet
Strain Description
Ensembl Transcript ID
ENSMUST00000030280
NCBI Transcript ID
NM_013913
Target Region
Exon 1~5
Size of Effective Region
~4.5 kb
Overview of Gene Research
ANGPTL3, short for angiopoietin-like protein 3, is a multifunctional secreted protein mainly expressed in the liver [3]. It belongs to a family of proteins that play a crucial role in lipid metabolism by inhibiting lipoprotein lipase and other lipases, often via forming a complex with ANGPTL8 [1,4]. Additionally, ANGPTL3 is involved in multiple signaling pathways such as LXR/ANGPTL3, thyroid hormone/ANGPTL3, insulin/ANGPTL3 and leptin/ANGPTL3, which are associated with various physiological and pathological processes [3].
Large-scale genetic studies in humans have shown that carriers of loss-of-function variants in ANGPTL3 have lower plasma LDL-C and triglyceride levels, and are at reduced risk of atherosclerotic cardiovascular disease [1,5]. In dyslipidemic mice, inhibition of Angptl3 with evinacumab led to a greater decrease in atherosclerotic lesion area and necrotic content compared to a control antibody [5]. Clinical studies in patients with different forms of dyslipidemia, including homozygous familial hypercholesterolemia and hypertrygliceridemic patients, have demonstrated that inactivation of ANGPTL3 using monoclonal antibodies, antisense oligonucleotides, or RNA interference therapies can markedly lower plasma LDL-C and triglyceride levels [1,2,6,7,8,9].
In conclusion, ANGPTL3 is a key regulator in lipid metabolism. Findings from loss-of-function studies in both humans and mice have revealed its significant role in reducing the risk of atherosclerotic cardiovascular disease by lowering lipid levels. These insights have provided a strong rationale for developing ANGPTL3-targeting therapies for treating dyslipidemia and related cardiovascular diseases [1,2,5,7,8].
References:
1. Kersten, Sander. . ANGPTL3 as therapeutic target. In Current opinion in lipidology, 32, 335-341. doi:10.1097/MOL.0000000000000789. https://pubmed.ncbi.nlm.nih.gov/34581310/
2. Bini, Simone, Tramontano, Daniele, Minicocci, Ilenia, D'Erasmo, Laura, Arca, Marcello. 2023. How ANGPTL3 Inhibition Will Help Our Clinical Practice? In Current atherosclerosis reports, 25, 19-29. doi:10.1007/s11883-022-01076-w. https://pubmed.ncbi.nlm.nih.gov/36607583/
3. Jiang, Shuang, Qiu, Guo-Hui, Zhu, Neng, Liao, Duan-Fang, Qin, Li. 2019. ANGPTL3: a novel biomarker and promising therapeutic target. In Journal of drug targeting, 27, 876-884. doi:10.1080/1061186X.2019.1566342. https://pubmed.ncbi.nlm.nih.gov/30615486/
4. Sylvers-Davie, Kelli L, Davies, Brandon S J. 2021. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. In American journal of physiology. Endocrinology and metabolism, 321, E493-E508. doi:10.1152/ajpendo.00195.2021. https://pubmed.ncbi.nlm.nih.gov/34338039/
5. Dewey, Frederick E, Gusarova, Viktoria, Dunbar, Richard L, Gromada, Jesper, Baras, Aris. 2017. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. In The New England journal of medicine, 377, 211-221. doi:10.1056/NEJMoa1612790. https://pubmed.ncbi.nlm.nih.gov/28538136/
6. Rosenson, Robert S, Gaudet, Daniel, Hegele, Robert A, Hellawell, Jennifer, Watts, Gerald F. 2024. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. In The New England journal of medicine, 391, 913-925. doi:10.1056/NEJMoa2404147. https://pubmed.ncbi.nlm.nih.gov/38809174/
7. Luo, Fei, Das, Avash, Khetarpal, Sumeet A, Rosenson, Robert S, Qamar, Arman. 2023. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. In Trends in cardiovascular medicine, 34, 215-222. doi:10.1016/j.tcm.2023.01.008. https://pubmed.ncbi.nlm.nih.gov/36746257/
8. Mohamed, Farzahna, Mansfield, Brett S, Raal, Frederick J. 2022. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. In Current atherosclerosis reports, 24, 959-967. doi:10.1007/s11883-022-01071-1. https://pubmed.ncbi.nlm.nih.gov/36367663/
9. Tomlinson, Brian, Wu, Qian-Yan, Zhong, Yi-Ming, Li, Yan-Hong. 2023. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors. In Journal of lipid and atherosclerosis, 13, 2-20. doi:10.12997/jla.2024.13.1.2. https://pubmed.ncbi.nlm.nih.gov/38299167/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
